Ovar

Primary diseas

   

 

AGO-OVAR 25 / ATHENA

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

 

 

Download

AGO-OVAR 25 Synopsis>>

 

AGO-OVAR 22 / YO 39523 (IMagyn050)

A Phase III, Multicenter, Randomized Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab for Patients with Newly-diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

 

 

Download

IMagyn050 German Synopsis>>

IMagyn050 German Patient Information>>

 

AGO-OVAR 20 / PAOLA-1

Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance  

 

   

Download

AGO-OVAR -20 German Synopsis>>

 AGO-OVAR 18 / TRINOVA-3

Phase III trial

A phase 3 randomized, double-blind, placebo-controlled, multicenter study of AMG 386 with paclitaxel and carboplatin as first-line treatment of subjects with FIGO stage III-IV epithelial ovarian, primary peritoneal or fallopian tube cancers

 

 

 

Download

AGO-OVAR 18 German Synopsis>>

AGO-OVAR 17

Phase III trial

A prospective randomized Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer.

The BOOST (Bevacizumab Ovarian Optimal Standard Treatment) Trial

 

 

Download

AGO-OVAR 17 German Synopsis>>

 

AGO-OVAR 16 / VEG110655
Phase III trial

A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

 

 

Download

AGO-OVAR 16 German Synopsis>>

AGO-OVAR 15
Phase II trial

An open-label, multicentre, randomized phase II study to compare the effects of Paclitaxel/Carboplatin and Lonafarnib to those of Paclitaxel/Carboplatin for first-line treatment of patients with epithelial ovarian cancer FIGO stages IIb - IV.

 

 

Download

AGO-OVAR 15 - German Synopsis>>

AGO-OVAR 12
Phase III trial

Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer.

 

 

Download

AGO-OVAR 12 - Study Report Synopsis>>

AGO-OVAR 11
Phase III trial

A randomised, two-arm, multi-centre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer.

 

 

Download

AGO-OVAR 11 - German Synopsis>>

AGO-OVAR 10
Phase III trial

A randomized, double blind, placebo controlled, multicenre trial of Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response to first line chemotherapie.

 

 

Download

AGO-OVAR 10 - German Synopsis>>

AGO-OVAR 9
Phase III trial

A multi-national randomized Phase III GCIG Intergroup Study comparing 1st line chemotherapy with Gemcitabine, Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in previously untreated patients with epithelial ovarian cancer FIGO stages I – IV.

 

Download

AGO-OVAR 9 - German Synopsis>>

 


 

Recurrent disease

   

 

AGO-OVAR 2.30 / ATALANTE

A randomized, double blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab

 

 

Download

ATALANTE Synopsis>>

 

AGO-OVAR 2.25 / GANNET53

A two-part, multicentre, international phase I and II trial assessing the safety and efficacy of the Hsp90 inhibitor ganetespib in combination with paclitaxel weekly in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer


   

 

Download

GANNET53 German Synopsis>>

AGO-OVAR 2.24 / MILO

A multinational, randomized, open-label phase 3 study of MEK162 vs. physician's choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube or primary peritoneum.


   

Download

AGO-OVAR -2.24 German Synopsis>>

AGO-OVAR 2.24 study sites>>

AGO-OVAR 2.23 / SOLO2

Phase III trial

A phase III randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients who are in complete or partial response following platinum based chemotherapy.

 

 

 

Download

AGO-OVAR 2.23 German Synopsis>>

http://ovariancancertrials.com/

AGO-OVAR 2.22 / NOVA

A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum sensitive ovarian cancer.

 

 

Download

AGO-OVAR 2.22 German Synopsis>>

AGO-OVAR 2.21

A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. An ENGOT/GCIG Trial.

 

 

Download

AGO-OVAR 2.21 German Synopsis>>

 

AGO-OVAR 2.20 / PENELOPE

Phase III trial

A two-part, randomized Phase III, double-blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. Placebo plus standard chemotherapy in women with recurrent platinum resistant epithelial ovarian cancer and low HER3 mRNA expression

 

 

Download

AGO-OVAR 2.20 >>

AGO-OVAR 2.19 / TRINOVA-2

Phase III trial

A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

 

 

 Download

AGO-OVAR 2.19 German Synopsis>>

AGO-OVAR 2.15 AURELIA / MO22224
Phase III trial

A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer

 

 

Download

AGO-OVAR 2.15 - German Synopsis>>

AGO-OVAR 2.12
Phase III trial

HECTOR (Hycamtin plus Carboplatin versus Established Regimens for the Treatment of Ovarian Cancer Relapse)

 

 

Download

AGO-OVAR 2.12 - German Synopsis>>

AGO-OVAR 2.11
Phase II trial

A randomized multicentre trial with SU11248 to evaluate dosage, schedule, tolerability, toxicity and effectiveness of al multitargeted receptor tyrosine kinase inhibitor monotherapie.

 

 

Download

AGO-OVAR 2.11 - German Synopsis>>

AGO-OVAR 2.10
Phase IIa trial

Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody removab® (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients.

 

 

Download

AGO-OVAR 2.10 - German Synopsis>>

AGO-OVAR 2.9
Phase III trial

A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX®) and Carboplatin vs Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Cancer in Late Relapse (>6 months).

 

 

Download

AGO-OVAR 2.9 - German Synopsis>>

AGO-OVAR 2.7
Phase III trial

Reinduktionstherapie mit Paclitaxel und Carboplatin plus Epoetin Alfa versus Reinduktionstherapie mit Paclitaxel und Carboplatin beim rezidivierenden platinsensiblen Ovarialkarzinom.

 

 

Download

AGO-OVAR 2.7 - German Synopsis>>

AGO-OVAR 2.3
Phase III trial

Topotecan versus Treosulfan in der Rezidivtherapie von Patientinnen mit Ovarialkarzinom nach Platin-/Paclitaxelvorbehandlung.

 

Download

AGO-OVAR 2.3 - German Synopsis>>

 


 

AGO-PRO 1 / Symptom Benefit

Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer?

 

 

Download

AGO-PRO 1 / Symptom Benefit German Synopsis>>

 


 

AGO-TR 1 / BRCA Screening

Incidence of BRCA in tumor samples in Ovarian Cancer Patients with primary or platinum sensitive recurrent ovarian cancer and correlation with germline status

 

 

Download

AGO-TR 1 German Synopsis and sites>>

 

 

 

Uterus

   

 

AGO-GYN 9 / ALIENOR

A multi-centre, randomized, open label, phase II trial of Bevacizumab
plus weekly Paclitaxel then Bevacizumab monotherapy in maintenance versus weekly Paclitaxel then observation in patients with relapsed ovarian sex-cord stromal tumours.


 

 

Download

AGO-GYN 9 German Synopsis>>

AGO-GYN 9 study sites>>

 

 

AGO-GYN 8

Efficacy, tolerability and safety of Temsirolimus in women with platinum-refractory ovarian carcinoma or advanced endometrial carcinoma

 

 

 

Download

AGO-GYN 8 German Synopsis>>

AGO-GYN 7
Phase II trial

Einsatz der Kombinationschemotherapie PegLiposomales Doxorubicin (PLD) und Carboplatin bei gynäkologischen Sarkomen und gemischt-mesenchymalen Tumoren.

 

 

Download

AGO GYN 7 - German Synopsis>>

AGO-GYN 6
Phase I/II trial

Feasibility Study of Pazopanib in Combination With Chemo in Gyn Tumors.

 

 

Download

AGO GYN 6 - German Synopsis>>

AGO-GYN 5

Phase II trial

Efficacy and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin, in women with LHRH receptor positive gynecological tumors.

 

 

Download

AGO GYN 5 - German Synospis>>

AGO-GYN 4
Phase I trial

A phase I open label dose escalation study of oral treatment with BIBF 1120 in combination with standard treatment of paclitaxel and carboplatin in patients with advanced gynaecological malignancies.

 

   

 


 

Vulva

AGO-CaRE 1

Chemo and Radiotherapy in Epithelial Vulvar Cancer

 

 

 Download

AGO-CaRE 1 - German Synopsis>>

 


 

Clinical trials in surgical settings

   

AGO-OVAR OP.2/DESKTOP II

Validation of a score of predictive factors for complete resection in paltium-sensitive ovarian cancer.

 

 

Download

AGO-OVAR OP.2 - German Synopsis>>

AGO-OVAR OP.3/LION

The role of lymphadnectomy in advanced ovarian cancer.

 

 

Download

AGO-OVAR OP.3 - German Synopsis>>

 

AGO-OVAR OP.4 / DESKTOP III

A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer

 

 

 

Download

AGO-OVAR OP.4 / DESKTOP III German Synopsis >>

 

AGO-OVAR OP.7 TRUST / AGO-OVAR 19

Trial on radical upfront surgery in advanced ovarian cancer

   

Download

TRUST German Synopsis>>

TRUST clinicaltrials.gov>>

 

AGO-OVAR OP.8 SHAPE

A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer

 

 

 

Download

SHAPE German Synopsis>>

 

 

PPE

   

AGO-PRO 2 / Mapisal

Treatment of Palmar-Plantar Erythrodysesthesia (PPE) in gynecologic oncology with Mapisal - an interventional, prospective, randomized, double-blind, placebo-controlled intergroup trial of the AGO and NOGGO Study Group

   

Download

Mapisal German Synopsis>>

Deutsche Version | Sitemap | Search | Imprint | Data Protection | Contact

© 2011 AGO Research GmbH | Admin-Login | Webdesign Hamburg